TheranosticTrials.org

Clinical Trial · NCT03288597

Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms

Overview

68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging associated with pathological findings and prognosis. The study was designed to confirm thet clinical values of dual imagings for neuroendocrine tumors.

Sponsor

Peking University First Hospital

Contacts

Lin Shen, Professor (CONTACT)

linshenpku@163.com

01088196561

ClinicalTrials.gov

NCT03288597

Drug / Compound

DOTANOC

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • Unresectable disease;
  • ECOG 0-1;
  • No prior antitumor treatment with chemotherapy targeting regimens for neuroendocrine carcimomas, no more than 2 systematic treatment for neuroendocrine tumors;
  • pathologically confirmed neuroendocrine, Ki67\>=10%;
  • Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
  • At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan \>=20mm, spiral CT scan \>=10mm, no prior radiation to measurable lesions);

Exclusion

  • In the process of antitumor therapy with effective response;